FDA Determines Regulatory Review Period for Alfapump to Assist With Patent Extension
February 06, 2026
February 06, 2026
WASHINGTON, Feb. 6 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration announced that it has calculated the regulatory review period for the medical device Alfapump. This determination follows an application by Sequana Medical NV to the U.S. Department of Commerce Patent and Trademark Office for a patent term extension.
Alfapump is an implanted device indicated for adult patients suffering from refractory or recurrent ascites due to liver cirrhos . . .
Alfapump is an implanted device indicated for adult patients suffering from refractory or recurrent ascites due to liver cirrhos . . .